Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Brian Erstad"'
Publikováno v:
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 5:354-357
Publikováno v:
Journal of Medical Economics. 24:1-13
With the increasing occurrence of infectious diseases in lower-and-middle-income countries (LMICs), emergency preparedness is essential for rapid response and mitigation. Economic evaluations of mitigation technologies and strategies have been recomm
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(Suppl 3)
Purpose Several studies have shown hydrocortisone to be beneficial in the treatment of vasopressor-refractory septic shock, but there are minimal data evaluating the efficacy of this fixed dosing regimen in overweight and obese patients. The purpose
813: OPIOID AND SEDATIVE USE IN ADULT ICUS: ADULT IATROGENIC WITHDRAWAL STUDY IN THE ICU (ALERT-ICU)
Autor:
Scott Bolesta, Kathryn Smith, Céline Gélinas, Marc Perreault, Lisa Burry, Rebekah Eadie, Federico Carini, Jamie Harpel, Ryan Stewart, Richard Riker, Brian Erstad
Publikováno v:
Critical Care Medicine. 51:398-398
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 25(10)
Several chemoimmunotherapy and targeted treatment regimens are approved as front-line therapies in chronic lymphocytic leukemia. We estimated for the 10-year cost-effectiveness of these treatment regimens and the economic burden of following the esti
Publikováno v:
Annals of hematology. 100(10)
In this population-based study, we used the SEER database (1985-2015) to examine survival outcomes in chronic lymphocytic leukemia (CLL) patients followed up to the era of advanced treatments including targeted therapies. Data were extracted for pati
Autor:
Nimer, Alkhatib, Nancy K, Sweitzer, Christopher S, Lee, Brian, Erstad, Marion, Slack, Mahdi, Gharaibeh, Jason, Karnes, Walter, Klimecki, Kenneth, Ramos, Ivo, Abraham
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 21(2)
The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjec
Autor:
Nimer S. Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Ivo Abraham
Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The third dimension (δ3) estimates prices on the basis of international drug price referencing methods. We describe this dimension’s methodology and present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b311a7a0a43f8f0300ff3269ad40192c
Publikováno v:
Critical Care Medicine. 50:765-765
Publikováno v:
Critical Care Medicine. 50:717-717